Related Experiment Video
Updated: Jul 2, 2026
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
A Greater Increase in Complement C5a Receptor 1 Level at Onset and a Smaller Decrease in Immunoglobulin G Level after
Torao Ishida1, Ken Takagi1, Guifeng Wang1
1Project for Advanced Science, Suzuka University of Medical Science, Suzuka 510-0293, Japan.
Insights
This study reveals distinct Complement C5a receptor 1 (C5aR1) and Immunoglobulin G (IgG) level changes in COVID-19 versus non-COVID-19 pneumonia. A novel statistical test identified these differences, crucial for patient care.
Area of Science:
- Immunology
- Virology
- Biostatistics
Background:
- Distinguishing COVID-19 from other pneumonias is critical for effective treatment.
- Complement C5a receptor 1 (C5aR1) and Immunoglobulin G (IgG) levels may serve as key indicators of disease severity and recovery.
Purpose of the Study:
- To compare changes in C5aR1 and IgG levels between COVID-19 and non-COVID-19 pneumonia patients.
- To identify potential biomarkers for differentiating disease trajectories and outcomes.
- To validate a novel statistical method for analyzing longitudinal biomarker data.
Main Methods:
- Systematic literature search of PubMed Central for individual patient data on C5aR1 and IgG levels in COVID-19 and non-COVID-19 pneumonia.
- Conventional statistical analysis of biomarker changes.
- Application of a novel two-tailed t-test utilizing regression line values for re-examination of non-significant changes.
Main Results:
- Conventional analyses failed to detect significant differences in C5aR1 and IgG levels.
- The novel t-test revealed a significantly greater increase in C5aR1 levels at onset in COVID-19 patients.
- The novel t-test indicated a significantly smaller decrease in IgG levels after recovery in COVID-19 patients compared to non-COVID-19 pneumonia.
Conclusions:
- The novel t-test is more sensitive in detecting subtle yet clinically relevant biomarker changes.
- C5aR1 and IgG level dynamics differ significantly between COVID-19 and non-COVID-19 pneumonia.
- This novel statistical approach holds promise for clinical application in managing COVID-19 patients.
Abstract:
(1) Background: It is our purpose to identify the differences in the changes in Complement C5a receptor 1 (C5aR1) levels showing the degree of inflammation at onset and Immunoglobulin G (IgG) levels showing the extent of survival of the virus fragments after recovery between coronavirus disease 2019 (COVID-19) and pneumonia coronavirus disease (non-COVID-19) for saving patients' lives. (2) Methods: First, the studies showing these markers' levels in individual patients before and after the passage of time were selected from the PubMed Central® databases with the keywords (((COVID-19) AND individual) NOT review) AND C5a/IgG. Then, no changes in these markers' levels with conventional analyses were selected from the studies. Finally, the no changes were reexamined with our new two-tailed t-test using the values on the regression line between initial levels and changed levels instead of the mean or median of changed levels as the expected values of changed levels. (3) Results: Not conventional analyses but our new t-test suggested a greater increase in C5aR1-levels at onset and a smaller decrease in IgG-levels after recovery in COVID-19 patients than non-COVID-19 patients. (4) Conclusion: Our new t-test also should be used in clinics for COVID-19 patients.
Related Concept Videos
01:27Complement System
01:27Cytomegalovirus Disease